Ultimately, clear distinction between focal cartilage injury and diffuse degenerative joint disease is essential to determine ACI eligibility, with emerging imaging, biomaterials, and scaffold innovations contributing to expanding its therapeutic window
Other innovative platforms such as gold nanoparticles (photothermal controlled release) (Vines et al., 2019), magnetic nanoparticles (magnetic targeting) and microfluidic chip systems integrate targeting, imaging and controlled release functions to promote the development of precision therapy
The anatomical structures involved are entirely different: adipose tissue has low vascular density and slow lymphatic drainage, while skeletal muscle is highly vascularised with direct venous return
Minimum effective frequency is 4 applications per week
Member Perk: 15% off any additional peptide purchases